- Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (2014-12-06)
Priscilla B Pujatti, Julie M Foster, Ciara Finucane, Chantelle D Hudson, Jerome C Burnet, Kerly F M Pasqualoto, Jair Mengatti, Stephen J Mather, Elaine B de Araújo, Jane K Sosabowski
PMID25479439
摘要
We evaluated and compared a new bombesin analog [Tyr-Gly5, Nle(14)]-BBN(6-14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT.
材料
产品编号
品牌
产品描述
Sigma-Aldrich
氯化钠, Molecular Biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
氯化钠, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%